Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder (AUD). At this stage, eleven participants have completed…

On 1 November 2018, following considerable popular pressure surrounding a select number of young children with treatment-resistant epilepsy who responded well to medicinal cannabis (and medicinal cannabis alone), regulations in the UK came into force to reschedule cannabis‑derived medicinal products to schedule 2 of the Misuse of Drugs Regulations 2001 and…